‘Ritlecitinib: unveiling hair regrowth for alopecia areata’

Alopecia Areata (AA) is an autoimmune disorder characterized by non-scarring hair loss on the scalp and other parts of the body. It is a complex medical condition associated with an impaired immune response in hair follicles. Various therapies are available for AA, including topical, systemic, and injectable treatments. However, their effectiveness varies, and no treatment consistently achieves and maintains remission. Therefore, this review aims to highlight the breakthrough advancement in treatment of AA i.e., the United State Food and Drug Administration (FDA) approved Ritlecitinib, the first and only oral treatment for moderate to severe alopecia areata in patients aged 12 and older. This approval represents a significant achievement in AA management, offering a targeted and effective treatment for those with more extensive hair loss.